<DOC>
	<DOCNO>NCT00767468</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase I trial study side effect best dose sorafenib treat patient locally advance metastatic liver cancer cirrhosis .</brief_summary>
	<brief_title>Sorafenib Treating Patients With Locally Advanced Metastatic Liver Cancer Cirrhosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate pharmacokinetic parameter sorafenib tosylate patient locally advance metastatic hepatocellular carcinoma Child-Pugh B cirrhosis . - To correlate pharmacokinetic parameter sorfenib tosylate hepatic retention clearance technetium Tc 99m mebrofenin ( MEB ) technetium Tc 99m sestamibi ( MIBI ) . Secondary - To establish tolerable dose sorafenib tosylate base degree liver dysfunction ( bilirubin ≤ 3 time upper limit normal [ ULN ] bilirubin &gt; 3 time ≤ 6 time ULN ) . - To correlate pharmacokinetics MEB MIBI dose-limiting toxicity sorafenib tosylate . - To explore whether increase bilirubin consist primarily conjugate unconjugated bilirubin response sorafenib tosylate . - To explore whether correlation increase bilirubin decrease clearance MEB and/or MIBI . - To explore whether correlation survival MRI characteristic associate high tumor VEGF level . - To assess VEGF level directly available biopsy sample use IHC . - To determine expression level hepatic transport protein ( i.e. , OATPs , Pgp , MRPs ) may correlate clearance sorafenib tosylate . - To explore whether correlation survival activation RAF/MEK/ERK pathway baseline . - To estimate median overall survival . OUTLINE : This multicenter study . Patients stratify accord degree hepatic dysfunction ( moderate [ bilirubin ≤ 3 time upper limit normal ( ULN ) ] v severe [ bilirubin &gt; 3 time ≤ 6 time ULN ] ) . Patients receive oral sorafenib tosylate twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo hepatic scintigraphy technetium Tc 99m mebrofinin ( MEB ) technetium Tc 99m sestamibi ( MIBI ) baseline . Blood urine sample collect periodically pharmacokinetic study . After completion study therapy , patient follow 3-4 week every 3 month thereafter .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Bilirubin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hepatocellular carcinoma ( HCC ) accord tissue histology* NOTE : *Recurrence previously resect HCC require tissue confirmation clear radiographic recurrence , opinion investigator Locally advance metastatic disease OR eligible surgical resection immediate liver transplantation ChildPugh class B cirrhosis Moderate hepatic dysfunction ( bilirubin ≤ 3 time upper limit normal [ ULN ] ) OR severe hepatic dysfunction ( bilirubin &gt; 3 time ≤ 6 time ULN ) No know brain metastasis unless metastasis stable &gt; 3 month PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy &gt; 12 week Hemoglobin &gt; 9.0 g/dL ANC &gt; 1,000/mm^3 Platelet count &gt; 45,000/mm^3 ALT AST &lt; 7 time ULN INR &lt; 2.0 Creatinine &lt; 1.7 time ULN OR creatinine clearance &gt; 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 2 week completion study treatment No history uncontrolled seizure , CNS disorder , psychiatric disability , opinion investigator , clinically significant , precludes give informed consent , interfere compliance oral drug intake No concurrent active malignancy No active clinically serious infection &gt; CTCAE grade 2 No know hypersensitivity sorafenib tosylate excipients No know suspect allergy sorafenib tosylate agent give course study No NYHA class III IV congestive heart failure No unstable angina No new onset angina ( i.e. , within past 3 month ) No myocardial infarction within past 6 month No cardiac ventricular arrhythmia require antiarrhythmic therapy No uncontrolled hypertension , define systolic blood pressure ( BP ) &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg , despite optimal medical management No thrombolic embolic event ( e.g. , cerebrovascular accident , include transient ischemic attack ) within past 6 month No pulmonary hemorrhage/bleeding event &gt; CTCAE grade 2 within past 4 week No hemorrhage/bleeding event &gt; CTCAE grade 3 within past 4 week No variceal bleed within past 90 day No know grade 2 3 esophageal varix No evidence history bleed diathesis coagulopathy No significant traumatic injury within past 4 week No serious nonhealing wound , ulcer , bone fracture No serious uncontrolled medical condition ( e.g. , uncontrolled ascites encephalopathy ) , opinion investigator , may compromise study participation No condition would impair patient 's ability swallow whole pill No malabsorption problem No active drug alcohol abuse PRIOR CONCURRENT THERAPY : No one prior therapy include , limited , follow : Systemic chemotherapy Hepatic artery infusion chemotherapy Chemoembolization Radioembolization Ablation At least 4 week since prior embolization , resection , ablation No prior RAF/MEK/ERKtargeting therapy VEGFtargeting therapy More 4 week since prior participation investigational drug study More 4 week since prior major surgery open biopsy No concurrent chronic anticoagulation 1 mg warfarin per day central venous catheter patency No concurrent St. John 's wort rifampin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>